BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, June 3, 2026
Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
Gastrointestinal RSS Feed RSS

Positive phase III results reported for Centocor's Crohn's disease treatment

April 7, 1997

Court rules in favor of Novopharm regarding generic ranitidine product

April 7, 1997

Budesonide cleared in Canada for Crohn's disease

April 4, 1997

Transdermal nicotine associated with clinical improvement in ulcerative colitis

April 2, 1997

Gilead's GS-840 enters phase II for chronic hepatitis B treatment

April 1, 1997

Extended treatment with Intron A for hepatitis C cleared by FDA

April 1, 1997

Shaman commences phase II trials of Provir in AIDS-related diarrhea

April 1, 1997

Kaken prepares broad-spectrum antiulcer agent

March 27, 1997

Axcan receives approvable letter for URSO from FDA

March 26, 1997

Synsorb Cd enters phase II

March 26, 1997
Previous 1 2 … 695 696 697 698 699 700 701 702 703 … 721 722 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 2, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Pancreas 3D hologram

    ASCO 2026: A revolution in pancreatic cancer

    BioWorld
    At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
  • Healthy (left) vs. cancerous bone marrow

    BMS’ mezigdomide doubles PFS in multiple myeloma

    BioWorld
    Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
  • Antibodies attacking cancer cell

    ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal

    BioWorld
    Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing